Cargando…

A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma

Background. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with rapid tumor progression and poor prognosis. This study was motivated by the lack of sensitive and specific PDAC biomarkers and aimed to identify a diagnostic, serum protein signature for PDAC. Methods. To mimic a real...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerdtsson, Anna S., Malats, Núria, Säll, Anna, Real, Francisco X., Porta, Miquel, Skoog, Petter, Persson, Helena, Wingren, Christer, Borrebaeck, Carl A. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4637476/ https://www.ncbi.nlm.nih.gov/pubmed/26587286 http://dx.doi.org/10.1155/2015/587250

Ejemplares similares

Tumor tissue protein signatures reflect histological grade of breast cancer
por: Skoog, Petter, et al.
Publicado: (2017)

Evaluation of Solid Supports for Slide- and Well-Based Recombinant Antibody Microarrays
por: Gerdtsson, Anna S., et al.
Publicado: (2016)

Protein Microarray Technologies for Detection and Identification of Bacterial and Protein Analytes
por: Wingren, Christer, et al.
Publicado: (2008)

Interfacing antibody-based microarrays and digital holography enables label-free detection for loss of cell volume
por: El-Schich, Zahra, et al.
Publicado: (2015)

Quantitative Proteomics Targeting Classes of Motif-containing Peptides Using Immunoaffinity-based Mass Spectrometry
por: Olsson, Niclas, et al.
Publicado: (2012)

Grading Breast Cancer Tissues Using Molecular Portraits
por: Olsson, Niclas, et al.
Publicado: (2013)

Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics
por: Delfani, Payam, et al.
Publicado: (2016)

Serum Protein Profiling of Systemic Lupus Erythematosus and Systemic Sclerosis Using Recombinant Antibody Microarrays
por: Carlsson, Anders, et al.
Publicado: (2011)

Multiplex profiling of serum proteins in solution using barcoded antibody fragments and next generation sequencing
por: Brofelth, Mattias, et al.
Publicado: (2020)

Proteomic Analysis and Discovery Using Affinity Proteomics and Mass Spectrometry
por: Olsson, Niclas, et al.
Publicado: (2011)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

SALL4‐related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features
por: Vienot, Angélique, et al.
Publicado: (2023)

Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
por: Schnipper, Julie, et al.
Publicado: (2020)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
por: Secrier, Maria, et al.
Publicado: (2016)

Differential Gene Expression Analysis of Placentas with Increased Vascular Resistance and Pre-Eclampsia Using Whole-Genome Microarrays
por: Centlow, M., et al.
Publicado: (2011)

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
por: Chen, Dung-Tsa, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma
por: Zhang, Deyu, et al.
Publicado: (2022)

Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
por: Ren, Min, et al.
Publicado: (2023)

Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma
por: Mascharak, Shamik, et al.
Publicado: (2023)

A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma
por: Haider, Syed, et al.
Publicado: (2014)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
por: Chen, Dongjie, et al.
Publicado: (2021)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma
por: Li, Tiandong, et al.
Publicado: (2023)

Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Time for a Personalized Approach?
por: Puleo, Amanda, et al.
Publicado: (2022)

A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma
por: Stratford, Jeran K., et al.
Publicado: (2010)

Correction: Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
Publicado: (2018)

A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma
por: Zhou, Chenhao, et al.
Publicado: (2019)

A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis
por: Mohamed Abd-El-Halim, Yousra, et al.
Publicado: (2021)

Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma
por: Sebastian, Nikhil T., et al.
Publicado: (2021)

An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021)

Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA
por: Wu, Huanwen, et al.
Publicado: (2022)

Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma
por: Fang, Lishan, et al.
Publicado: (2023)

Targeting Pancreatic Ductal Adenocarcinoma Acidic Microenvironment
por: Cruz-Monserrate, Zobeida, et al.
Publicado: (2014)

A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma
por: Satoi, Sohei, et al.
Publicado: (2016)

Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study
por: Brand, Randall E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_26epuml9t8eq8966tg5ai9tdua